Clinical Trials Browser

Phase 2 × Breast Neoplasms × apatinib × Clear all

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03982485 2024-04-30

APP

Phase 2 Active not recruiting

Breast Neoplasms

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Phase 2 Unknown

Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02878057 2021-01-27

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Phase 2 Completed

30 enrolled 12 charts

Breast Neoplasms

NCT03394287 2020-10-23

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Phase 2 Completed

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03735082 2018-11-08

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03457467 2018-03-07

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT01176669 2015-09-09

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01653561 2013-12-03

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms